1. The Atezolizumab group demonstrated significantly greater progression-free and overall survival among patients with metastatic, persistent, or recurrent cervical cancer. ...
1. Programmed death-ligand 1 copy number loss was identified as an independent risk factor for the progression of the disease ...
1. Pembrolizumab-alone or pembrolizumab-chemotherapy prolonged overall survival vs cetuximab-chemotherapy in the PD-L1 positive population 2. While pembrolizumab-chemotherapy found an improved ...
1. Adjuvant pembrolizumab significantly improved disease-free survival in comparison to placebo in PD-L1 unselected non-small-cell lung cancer patients who underwent ...
Click to read this study in the Journal of Clinical Oncology.
1. High tumour mutation burden levels were associated with improvements in objective response rate, progression-free survival, and overall survival, with ...
1. The overall response rate was 54.8% in the intention-to-treat group while it was 59.0% in the efficacy-evaluable group. 2. ...
1. Patients receiving pembrolizumab with or without platinum-based chemotherapy experienced longer progression-free and overall survival than the placebo group. 2. ...
Atezolizumab showed a benefit for disease-free survival in patients with stage II-IIIA NSCLC compared to best supportive treatment. Grade 3 ...
1. Atezolizumab showed a benefit for disease-free survival in patients with stage II-IIIA NSCLC compared to best supportive treatment. 2. ...
